NKG2A & CD94

NKG2A & CD94 분자 정보

영어 이름NK cell lectin-like receptor subfamily C member 1시판 약물 수0
임상 약물 수6표적 별명CD159a,NKG2A,KLRC1,Killer Cell Lectin Like Receptor C1,Killer Cell Lectin-Like Receptor Subfamily C, Member 1,CD159 Antigen-Like Family Member A,NKG2-1/B Activating NK Receptor,NKG2-A/B-Activating NK Receptor,NK Cell Receptor A,NKG2-A/NKG2-B Type II Integral Membrane Protein,NKG2-A/B Type II Integral Membrane Protein,Natural Killer Group Protein 2,Natural Killer Cell Lectin,C-Lectin Type II Protein,CD159a Antigen,NKG2,NKG2-B,NKG2-A
최고 연구 개발 단계Phase 3 Clinical
영어 이름NK cell lectin-like receptor subfamily C member 1
표적 별명CD159a,NKG2A,KLRC1,Killer Cell Lectin Like Receptor C1,Killer Cell Lectin-Like Receptor Subfamily C, Member 1,CD159 Antigen-Like Family Member A,NKG2-1/B Activating NK Receptor,NKG2-A/B-Activating NK Receptor,NK Cell Receptor A,NKG2-A/NKG2-B Type II Integral Membrane Protein,NKG2-A/B Type II Integral Membrane Protein,Natural Killer Group Protein 2,Natural Killer Cell Lectin,C-Lectin Type II Protein,CD159a Antigen,NKG2,NKG2-B,NKG2-A
시판 약물 수0
임상 약물 수6
최고 연구 개발 단계Phase 3 Clinical

NKG2A & CD94 제품 목록

  • 속성

    Protein (10)

  • 제품 라이브러리

    온라인 (10)

  • Human (5)Cynomolgus (2)Mouse (3)

  • 태그

    Mouse IgG Fc Tag (1)Fc Tag & Avi Tag (3)His Tag (3)Fc Tag (2)His Tag & Avi Tag (1)

  • 마커

    Unconjugated (6)Biotin-labeled (4)

NKG2A & CD94분자 배경

CD94 plays a role as a receptor for the recognition of MHC class I HLA-E molecules by NK cells and some cytotoxic T-cells. KLRD1 (CD94) is an antigen preferentially expressed on NK cells and is classified as a type II membrane protein because it has an external C terminus. NKG2A/CD159a is a transmembrane protein belonging to the CD94/NKG2 family of C-type lectin-like receptors that inhibits innate immune system activation. CD94 pairs with the NKG2 molecule as a heterodimer. The CD94/NKG2 complex, on the surface of natural killer cells interacts with Human Leukocyte Antigen (HLA)-E on target cells.

NKG2A & CD94분자 별명

NKG2A & CD94

임상 약물 정보

영어 이름연구 코드연구 개발 단계회사적응증임상 시험
MonalizumabNNC-0141-0000-0100; NNC 0141-0000-0100; IPH-22XX; IPH-22; NN-8765; IPH-2201Phase 3 ClinicalNovo Nordisk A/SArthritis, Rheumatoid; Bone Marrow Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Colorectal Neoplasms; Esophageal adenocarcinoma; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Genital Neoplasms, Female; Head and Neck Neoplasms; Hematologic Neoplasms; Inflammation; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Oral Squamous Cell Carcinoma; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Urinary Bladder Neoplasms
상세
BMS-986315BMS-986315Phase 2 ClinicalBristol-Myers Squibb CompanyCarcinoma, Non-Small-Cell Lung; Solid tumours
상세
S-095029S-095029Phase 2 ClinicalInstitut De Recherches Internationales ServierCarcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Microsatellite instability-high cancer; Mismatch Repair Deficient Cancer; Solid tumours; Stomach Neoplasms
상세
HY000102HY-0102; HY-000102Phase 2 ClinicalShanghai HyaMab Biotech Co LtdPancreatic Neoplasms; Solid tumours
상세
XB-628XB628Phase 1 ClinicalExelixis IncNeoplasms; Solid tumours
상세
BRY-805BRY805; BRY-805Phase 1 ClinicalHisun Biopharmaceutical Co Ltd, Zhejiang BioRay Biopharmaceuticals Co LtdSolid tumours
상세
  • 분자 정보
  • 제품 목록
  • 임상 약물 정보
문의하기

전화
글로벌: +1 800-810-0816 (무료)
아시아태평양: +86 400-682-2521

주소 서울특별시 송파구 법원로11길 11, 제3층 제비-314,315호